切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 199 -202. doi: 10.3877/cma.j.issn.1674-1366.2022.03.012

综述

甲状腺癌131I治疗后相关唾液腺炎的诊疗进展
赵佳雄1, 南欣荣1,(), 孟兵1, 李瑞芳1, 闫星泉1   
  1. 1. 山西医科大学第一医院口腔颌面外科,太原 030001
  • 收稿日期:2022-01-03 出版日期:2022-06-01
  • 通信作者: 南欣荣

Advances in diagnosis and treatment of sialadenitis associated with thyroid cancer after 131I therapy

Jiaxiong Zhao1, Xinrong Nan1,(), Bing Meng1, Ruifang Li1, Xingquan Yan1   

  1. 1. Department of Oral and Maxillofacial Surgery, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2022-01-03 Published:2022-06-01
  • Corresponding author: Xinrong Nan
引用本文:

赵佳雄, 南欣荣, 孟兵, 李瑞芳, 闫星泉. 甲状腺癌131I治疗后相关唾液腺炎的诊疗进展[J]. 中华口腔医学研究杂志(电子版), 2022, 16(03): 199-202.

Jiaxiong Zhao, Xinrong Nan, Bing Meng, Ruifang Li, Xingquan Yan. Advances in diagnosis and treatment of sialadenitis associated with thyroid cancer after 131I therapy[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(03): 199-202.

131I相关唾液腺炎是甲状腺癌131I治疗后的常见并发症,其主要机理尚未完全明确,研究认为唾液腺导管上皮细胞的钠碘同向转运体(NIS)对碘的吸收,导致导管急性或慢性炎症。最新研究结果显示,该病可能还与水通道蛋白(AQP)有关。131I相关唾液腺炎临床表现及治疗方案基本等同于常规的急慢性唾液腺炎,临床上以预防为主。本文针对近年来对131I相关唾液腺炎病理、生理、诊断及治疗研究进展作一综述。

131I-related sialadenitis is a common complication after thyroid cancer 131I treatment, and its main mechanism is not yet fully understood. Studies suggest that the absorption of iodine by the sodium-iodine symporter (NIS) of salivary gland duct epithelial cells leads to acute or chronic inflammation of the duct. The latest research results show that it may also be related to aquaporin (AQP) . The clinical manifestations and treatment plan of 131I-related sialadenitis are basically equivalent to conventional acute and chronic sialadenitis, and prevention is the main clinical treatment. This article reviews the recent research progress on the pathology, physiology, diagnosis and treatment of 131I-related sialadenitis.

[1]
Ehrhardt JD Jr, Gulec SA. Birth of the beta-knife thyroidectomy:The radiance of saul hertz [J]. Am Surg2022:313482110604 63. DOI:10.1177/00031348211060463.
[2]
Sánchez Barrueco A, González Galán F, Alcalá Rueda I,et al. Incidence and risk factors for radioactive iodine-induced sialadenitis[J]. Acta Otolaryngol2020140(11):959-962. DOI:10.1080/00016489.2020.1802507.
[3]
Yasmin T, Adnan S, Younis MN,et al. Comparing high and low-dose radio-iodine therapy in thyroid remnant ablation among intermediate and low-risk papillary thyroid carcinoma patients-single centre experience[J]. Dose Response202119(4):155 93258211062775. DOI:10.1177/15593258211062775.
[4]
Lei L, Velasco O, Nobay F. Iodide mumps:A case report of complicated radioactive iodine causing sialadenitis[J]. Am J Emerg Med201230(3):512.e5-512.e6. DOI:10.1016/j.ajem.2010.12.037.
[5]
Nabaa B, Takahashi K, Sasaki T,et al. Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT:The significance of changes in volume and attenuation of the glands[J]. Am J Neuroradiol201233(10):1964-1970. DOI:10.3174/ajnr.A3063.
[6]
Thorpe RK, Foggia MJ, Marcus KS,et al. Sialographic analysis of radioiodine-associated chronic sialadenitis[J]. Laryngoscope2021131(5):E1450-E1456. DOI:10.1002/lary.29279.
[7]
Lu L, Shan F, Li W,et al. Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer[J]. Biomed Res Int2016:4376720. DOI:10.1155/2016/4376720.
[8]
Oh JM, Kalimuthu S, Gangadaran P,et al. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor(K905-0266)excavated by high-throughput NIS(sodium iodide symporter)enhancer screening platform using dual reporter gene system[J]. Oncotarget20189(6):7075-7087. DOI:10.18632/oncotarget.24159.
[9]
Prendes BL, Orloff LA, Eisele DW. Therapeutic sialendoscopy for the management of radioiodine sialadenitis[J]. Arch Otolaryngol Head Neck Surg2012138(1):15-19. DOI:10.1001/archoto.2011.215.
[10]
Geres AE, Mereshian PS, Fernández S,et al. Sialadenitis after radioiodine therapy. Analysis of factors that influence the response to medical treatment[J]. Endocrinol Nutr201562(10):493-498. DOI:10.1016/j.endonu.2015.07.006.
[11]
Wu CB, Xi H, Zhou Q,et al. Sialendoscopy-assisted treatment for radioiodine-induced sialadenitis[J]. J Oral Maxillofac Surg201573(3):475-481. DOI:10.1016/j.joms.2014.09.025.
[12]
李审绥,吴沉洲,乔翔鹤,等.辐射损伤唾液腺机制及治疗的研究进展[J].华西口腔医学杂志202139(1):99-104. DOI:10.7518/hxkq.2021.01.015.
[13]
Peng X, Wu Y, Brouwer U,et al. Cellular senescence contributes to radiation-induced hyposalivation by affecting the stem/progenitor cell niche[J]. Cell Death Dis202011(10):854. DOI:10.1038/s41419-020-03074-9.
[14]
Gonzalez ME, Muttikkal TJE, Rehm PK. Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen®(recombinant human thyroid stimulating hormone-thyrotropin alfa)[J]. J Radiol Case Rep20159(6):44-49. DOI:10.3941/jrcr.v9i6.2220.
[15]
Katada R, Tanaka J, Takamatsu K,et al. Induction of salivary gland-like cells from epithelial tissues transdifferentiated from mouse embryonic fibroblasts[J]. Biochem Biophys Res Commun2022586:55-62. DOI:10.1016/j.bbrc.2021.11.064.
[16]
Feng X, Wu Z, Xu J,et al. Dietary nitrate supplementation prevents radiotherapy-induced xerostomia[J]. Elife202110:e70710. DOI:10.7554/eLife.70710.
[17]
Klein Hesselink EN, Brouwers AH, de Jong JR,et al. Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma:A prospective study[J]. J Nucl Med201657(11):1685-1691. DOI:10.2967/jnumed.115.169888.
[18]
Mizrachi A, Cotrim AP, Katabi N,et al. Radiation-induced microvascular injury as a mechanism of salivary gland hypofunction and potential target for radioprotectors[J]. Radiat Res2016186(2):189-195. DOI:10.1667/RR14431.1.
[19]
Cotrim AP, Sowers A, Mitchell JB,et al. Prevention of irradiation-induced salivary hypofunction by microvessel protection in mouse salivary glands[J]. Mol Ther200715(12):2101-2106. DOI:10.1038/sj.mt.6300296.
[20]
Xu J, Yan X, Gao R,et al. Effect of irradiation on microvascular endothelial cells of parotid glands in the miniature pig[J]. Int J Radiat Oncol Biol Phys201078(3):897-903. DOI:10.1016/j.ijrobp.2010.05.048.
[21]
Liu Z, Dong L, Zheng Z,et al. Mechanism,prevention,and treatment of radiation-induced salivary gland injury related to oxidative stress[J]. Antioxidants(Basel)202110(11):1666. DOI:10.3390/antiox10111666.
[22]
Yamazaki H, Suzuki G, Aibe N,et al. Reirradiation for rare head and neck cancers:Orbit,auditory organ,and salivary glands[J]. Cureus202214(2):e22727. DOI:10.7759/cureus.22727.
[23]
Moloney EC, Brunner M, Alexander AJ,et al. Quantifying fibrosis in head and neck cancer treatment:An overview[J]. Head Neck201537(8):1225-1231. DOI:10.1002/hed.23722.
[24]
Lalkovicova M. Neuroprotective agents effective against radiation damage of central nervous system[J]. Neural Regen Res202217(9):1885-1892. DOI:10.4103/1673-5374.335137.
[25]
An YS, Yoon JK, Lee SJ,et al. Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer[J]. Ann Nucl Med201327(4):386-391. DOI:10.1007/s12149-013-0697-5.
[26]
Krčálová E, Horáček J, Gabalec F,et al. Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation[J]. Eur J Oral Sci2020128(3):204-210. DOI:10.1111/eos.12689.
[27]
Singer MC, Marchal F, Angelos P,et al. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer:American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology,ophthalmology,nuclear medicine and endocrinology[J]. Head Neck202042(11):3446-3459. DOI:10.1002/hed.26417.
[28]
Son H, Lee SM, Yoon RG,et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer[J]. Hell J Nucl Med201720(1):62-70. DOI:10.1967/s002449910508.
[29]
Choi JS, Hong SB, Hyun IY,et al. Effects of salivary secretion stimulation on the treatment of chronic radioactive iodine-induced sialadenitis[J]. Thyroid201525(7):839-845. DOI:10.1089/thy.2014.0525.
[30]
Gil-Montoya JA, Silvestre FJ, Barrios R,et al. Treatment of xerostomia and hyposalivation in the elderly:A systematic review[J]. Med Oral Patol Oral Cir Bucal201621(3):e355-e366. DOI:10.4317/medoral.20969.
[31]
Karagozoglu KH, Vissink A, Forouzanfar T,et al. Sialendoscopy increases saliva secretion and reduces xerostomia up to 60 weeks in Sjögren′s syndrome patients:A randomized controlled study[J]. Rheumatology(Oxford)202160(3):1353-1363. DOI:10.1093/rheumatology/keaa284.
[32]
Jentzen W, Richter M, Nagarajah J,et al. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging[J]. EJNMMI Phys20141(1):100. DOI:10.1186/s40658-014-0100-1.
[33]
Zhang T, Liu C, Ma S,et al. Protective effect and mechanism of action of rosmarinic acid on radiation-induced parotid gland injury in rats[J]. Dose Response202018(1):15593258209 07782. DOI:10.1177/1559325820907782.
[34]
Li X, Zhao YN, Zhang LQ,et al. Differences between radioactive iodine-induced sialadenitis and chronic obstructive parotitis[J]. Int J Oral Maxillofac Surg2021:S0901-5027(21)00391-X. DOI:10.1016/j.ijom.2021.11.003.
[35]
Liu X, Cotrim A, Teos L,et al. Loss of TRPM2 function protects against irradiation-induced salivary gland dysfunction[J]. Nat Commun20134:1515. DOI:10.1038/ncomms2526.
[36]
Timiri Shanmugam PS, Dayton RD, Palaniyandi S,et al. Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia[J]. Hum Gene Ther201324(6):604-612. DOI:10.1089/hum.2012.235.
[1] 孙帼, 谢迎东, 徐超丽, 杨斌. 超声联合临床特征的列线图模型预测甲状腺乳头状癌淋巴结转移的价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 734-742.
[2] 张桂萍, 张璐, 侯怡卿, 陈煜东, 詹维伟. 超声引导下甲状腺细针穿刺活检在未成年人甲状腺结节诊断中的应用[J]. 中华医学超声杂志(电子版), 2021, 18(09): 822-827.
[3] 李婷婷, 卢漫, 巫明钢, 王璐, 魏婷, 廖继芬, 邹世彬, 李妍洁. 计算机辅助诊断系统对甲状腺结节的诊断价值研究[J]. 中华医学超声杂志(电子版), 2019, 16(09): 660-664.
[4] 陈易来, 詹维伟, 周伟. 超声评估甲状腺乳头状癌不同分区转移性淋巴结的价值[J]. 中华医学超声杂志(电子版), 2019, 16(09): 647-652.
[5] 张静雯, 詹维伟, 董屹婕, 徐上妍, 贾晓红. 术前超声评估甲状腺乳头状癌N分期及不同N分期的影响因素[J]. 中华医学超声杂志(电子版), 2019, 16(02): 126-130.
[6] 王勇, 王玲. 甲状腺癌术后碘131联合甲状腺激素应用效果分析[J]. 中华普外科手术学杂志(电子版), 2020, 14(06): 616-619.
[7] 王猛, 郑鲁明, 李小磊, 周鹏, 王刚, 朱见, 厉彦辰, 贺青卿. 经口腔前庭机器人甲状腺癌择区性颈淋巴结清扫的初步探讨[J]. 中华腔镜外科杂志(电子版), 2022, 15(06): 347-351.
[8] 赵宁. 全乳晕入路腔镜甲状腺癌根治术[J]. 中华腔镜外科杂志(电子版), 2020, 13(04): 0-0.
[9] 周鹏, 贺青卿, 庄大勇, 朱见, 王猛, 李小磊, 岳涛, 王丹, 李丹丹. 达芬奇机器人与开放性手术在肿瘤直径大于1 cm甲状腺癌中的对照研究[J]. 中华腔镜外科杂志(电子版), 2019, 12(03): 133-137.
[10] 张彬, 韩宗辉, Bikash Rai. 经口腔达芬奇机器人甲状腺手术初步经验[J]. 中华腔镜外科杂志(电子版), 2018, 11(04): 234-237.
[11] 赵雪琴, 苏学峰, 任东伟, 崔冰冰, 王振东, 李慧. DDX5在甲状腺癌中的表达及其临床意义[J]. 中华临床医师杂志(电子版), 2023, 17(04): 386-390.
[12] 武振, 王永坤, 姚玉民. 直径1~4 cm的分化型甲状腺癌的诊治进展[J]. 中华临床医师杂志(电子版), 2021, 15(02): 149-152.
[13] 辛玉晶, 陈毅, 王亚楠, 杨伊, 周翔. 超声引导125I粒子腹腔神经节植入术治疗进展期胰腺癌疼痛的疗效分析[J]. 中华介入放射学电子杂志, 2020, 08(01): 38-43.
[14] 李良辉, 吴国洋, 卢毅卓, 林福生, 陈丽娟, 陈小敏, 梁成强. 腹腔镜袖状胃切除术+经口腔前庭腔镜甲状腺癌根治术治疗重度肥胖合并双侧甲状腺癌一例报道[J]. 中华肥胖与代谢病电子杂志, 2022, 08(03): 214-216.
[15] 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 中国医师协会外科医师分会甲状腺外科医师委员会. 肥胖代谢病合并甲状腺癌外科治疗专家共识(2021版)[J]. 中华肥胖与代谢病电子杂志, 2022, 08(01): 9-14.
阅读次数
全文


摘要